Zobrazeno 1 - 10
of 31
pro vyhledávání: ''
Autor:
Mariana Petaccia de Macedo, Carlos Barrios, Eduardo Caetano Albino da Silva, Gustavo Werutsky, Clovis Klock, G. Borges, Christina Shiang, Fernando Silva de Moura, Vladmir Cláudio Cordeiro de Lima, Luiz H. Araujo, Eldsamira Mascarenhas, Paulo Ricardo Santos Nunes Filho, Pedro De Marchi, Helano C. Freitas, Facundo Zaffaroni, Patricia Pacheco Viola, A. Gelatti, Lisandro Ferreira Lopes, Mauro Zukin, Ana Maria Franco Gaiger, Clarissa Mathias
Publikováno v:
Clinical Lung Cancer. 21:e511-e515
Introduction We analyzed the prevalence of non–small-cell lung cancer (NSCLC) with a programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) of ≥ 50% and compared the results with the existing data from clinical trials and databases f
Autor:
Jacques Margery, Martine Antoine, Gérard Zalcman, Olivier Molinier, Claire Danel, Clarisse Audigier-Valette, Alexandra Langlais, Julien Mazieres, Laurent Greillier, Emmanuel Bergot, Solenn Brosseau, Franck Morin, Sylvie Lantuejoul, Isabelle Rouquette, Isabelle Monnet, Arnaud Scherpereel, Valérie Gounant, Denis Moro-Sibilot, Romain Corre, Guénaëlle Levallet
Publikováno v:
Clinical Lung Cancer
Clinical Lung Cancer, Elsevier, 2019, 20 (5), pp.e564-e575. ⟨10.1016/j.cllc.2019.04.010⟩
Clinical Lung Cancer, 2019, 20 (5), pp.e564-e575. ⟨10.1016/j.cllc.2019.04.010⟩
Clinical Lung Cancer, Elsevier, 2019, 20 (5), pp.e564-e575. ⟨10.1016/j.cllc.2019.04.010⟩
Clinical Lung Cancer, 2019, 20 (5), pp.e564-e575. ⟨10.1016/j.cllc.2019.04.010⟩
CERVOXY CLIN; International audience; Background - Anticancer immune responses are negatively regulated by programmed cell death 1 (PD-1) T-cell membrane protein interaction with its ligand, programmed death ligand 1 (PD-L1), on cancer cells. We soug
Autor:
Elisabeth J. Rushing, Walter Weder, Max Lacour, Seok-Yun Lee, Alex Soltermann, Stefanie Hiltbrunner, Alessandra Curioni-Fontecedro, Davide Soldini
Publikováno v:
Clinical Lung Cancer. 20:391-396
Background Despite recent studies, the effect of chemotherapy on programmed death-ligand 1 (PD-L1) expression remains controversial. In this study, we investigated whether PD-L1 expression is affected by platinum-based chemotherapy. Furthermore, we e
Publikováno v:
Clinical Lung Cancer. 19:e551-e558
Background The benefits of immune checkpoint inhibitors for first-line treatment in patients with lung adenocarcinoma harboring EGFR mutations are unclear. The effects of ICIs depend on the tumor microenvironment (TME). Differences in TME properties
Autor:
Ettore D'Argento, Antonella Cannella, Chiara Forcella, Michele Milella, Maurizio Martini, Emilio Bria, Emanuele Vita, Alessio Stefani, Carmine Carbone, Isabella Sperduti, M. Ribelli, Vincenzo Di Noia, P. Damiano, Sara Pilotto, Giampaolo Tortora, Miriam Grazia Ferrara, Geny Piro, Mirna Bilotta
Publikováno v:
Clinical lung cancer. 22(4)
Rapid disease progression of patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) has been recently associated with tumor heterogeneity, which may be mirrored by coexisting concomitant alterations.
Autor:
Xuefei Li, Tao Jiang, Chao Zhao, Qinrui Tian, Likun Hou, Shengxiang Ren, Wei Zhang, Guanghui Gao, Yayi He, Fengying Wu, Yiwei Liu, Chunyan Wu, Yingying Pan, Zhengwei Dong, Yan Wang, Shuo Yang, Jing Zhao, Jun Zhang, Caicun Zhou, Fred R. Hirsch
Publikováno v:
Clinical Lung Cancer. 19:e421-e430
Introduction Programmed death-ligand 1 (PD-L1) expression using immunohistochemistry is approved by the US Food and Drug Administration to guide treatment with anti-programmed death-1/PD-L1 monoantibodies. However, intratumoral heterogeneity of PD-L1
Publikováno v:
Clinical Lung Cancer. 18:e357-e361
Biopsy, brushing, and transbronchial needle aspiration (TBNA) are the most common methods used for the diagnosis of small cell lung cancer during the same diagnostic bronchoscopic procedure. However, it is not clear which method provides better resul
Autor:
Lea Knez, Matjaž Zwitter, Aleksander Sadikov, Tanja Cufer, Izidor Kern, Karmen Stanic, Nina Turnsek Hitij
Publikováno v:
Clinical Lung Cancer. 18:e187-e196
Introduction The sensitivity and specificity of immunohistochemistry (IHC) was compared with the standard polymerase chain reaction (PCR)-based method for detecting common activating epidermal growth factor receptor ( EGFR ) mutations in non–small-
Autor:
Nabil F. Saba, Lydia Koenig, Yuxiang Wang, Dong M. Shin, Hongpeng Fu, Zhuo Georgia Chen, Fadlo R. Khuri
Publikováno v:
Clinical Lung Cancer. 18:e203-e210
Objectives Compelling evidence demonstrates that CXC-chemokine receptor 4 (CXCR4) is involved in tumor invasion, angiogenesis, metastasis, and resistance to chemotherapy in addition to being one of the coreceptors for T-tropic human immunodeficiency
Autor:
Seung Joon Kim, In-Ho Kim, Jin Hyoung Kang, Young Kyoon Kim, Ie Ryung Yoo, Jieun Lee, Jae Kil Park, Tae-Jung Kim, Kyo-Young Lee, In Hee Lee, Yeon Sil Kim, Sook Whan Sung, Sook Hee Hong, Jung-Oh Kim
Publikováno v:
Clinical Lung Cancer. 17:e31-e43
Background Several studies have suggested risk factors for poor survival in stage IB non–small-cell lung cancer (NSCLC) patients. However, these factors are not definite indicators of adjuvant chemotherapy for stage IB cancer, and most of them can